Northwestern University researchers developed an AI-driven generative model capable of resolving gene combination patterns underlying complex diseases like diabetes and cancer, surpassing traditional single-gene approaches. Separately, an open-source AI model from MIT and Recursion Pharmaceuticals predicts small-molecule binding affinities and protein complex structures, addressing major challenges in drug discovery pipelines.